Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Suzetrigine: FDA-Approved Nav1.8 Inhibitor Offers Breakthrough Non-Opioid Relief for Moderate to Severe Acute Pain
Drug Insights
3 min read
Suzetrigine: FDA-Approved Nav1.8 Inhibitor Offers Breakthrough Non-Opioid Relief for Moderate to Severe Acute Pain
14 February 2025
Suzetrigine received approval from the FDA on January 30, 2025, as a small-molecule pharmaceutical for the treatment of moderate to severe acute pain in adults.
Read →
FDA-Approved Combination of Meloxicam and Rizatriptan Offers Dual-Action Relief for Migraine Treatment
Drug Insights
4 min read
FDA-Approved Combination of Meloxicam and Rizatriptan Offers Dual-Action Relief for Migraine Treatment
14 February 2025
The combination drug Meloxicam and Rizatriptan, received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025, for the treatment of migraine.
Read →
Limertinib: A Novel Third-Generation EGFR-TKI Approved in China
Drug Insights
3 min read
Limertinib: A Novel Third-Generation EGFR-TKI Approved in China
14 February 2025
Limertinib is a newly developed small-molecule chemical drug, specifically designed as an inhibitor targeting the epidermal growth factor receptor (EGFR) T790M mutation.
Read →
Senaparib: A Next-Generation PARP1/2 Inhibitor Approved in China
Drug Insights
3 min read
Senaparib: A Next-Generation PARP1/2 Inhibitor Approved in China
14 February 2025
Senaparib is a next-generation, highly potent PARP1/2 inhibitor developed by IMPACT Therapeutics.
Read →
Prusogliptin: A Novel DPP-4 Inhibitor Approved in China
Drug Insights
3 min read
Prusogliptin: A Novel DPP-4 Inhibitor Approved in China
14 February 2025
Prusogliptin, developed by CSPC Ouyi Pharmaceutical, is a novel oral dipeptidyl peptidase-4 (DPP-4) inhibitor that was approved by NMPA on January 8, 2025.
Read →
Finotonlimab: A Promising Anti-PD-1 Antibody for Solid Tumors
Drug Insights
3 min read
Finotonlimab: A Promising Anti-PD-1 Antibody for Solid Tumors
14 February 2025
Finotonlimab, developed by Sinocelltech, is a recombinant humanized anti-programmed death receptor-1 (PD-1) monoclonal antibody.
Read →
Breakthrough Antibody Drugs Approved in January 2025
Drug Highlight
3 min read
Breakthrough Antibody Drugs Approved in January 2025
13 February 2025
In January 2025, multiple antibody-based therapies received global regulatory approvals, offering new hope for the treatment of various diseases.
Read →
Efsubaglutide Alfa: A Novel GLP-1 Fusion Protein Revolutionizing Type 2 Diabetes
Drug Insights
3 min read
Efsubaglutide Alfa: A Novel GLP-1 Fusion Protein Revolutionizing Type 2 Diabetes
13 February 2025
Efsubaglutide Alfa received its first regulatory approval in China on January 24, 2025, from the National Medical Products Administration (NMPA).
Read →
Garadacimab: A Novel FXIIa-Targeting Monoclonal Antibody for Hereditary Angioedema
Drug Insights
3 min read
Garadacimab: A Novel FXIIa-Targeting Monoclonal Antibody for Hereditary Angioedema
13 February 2025
Garadacimab is an innovative, fully human IgG4 monoclonal antibody specifically designed to target activated Factor XII (FXIIa).
Read →
Datopotamab Deruxtecan: A Novel ADC Targeting Trop-2 for Advanced Breast Cancer
Drug Insights
4 min read
Datopotamab Deruxtecan: A Novel ADC Targeting Trop-2 for Advanced Breast Cancer
13 February 2025
Datopotamab Deruxtecan (Dato-DXd) is a Trop-2-targeting antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca.
Read →
Recaticimab: A Novel PCSK9-Targeting Monoclonal Antibody for Hypercholesterolemia
Drug Insights
3 min read
Recaticimab: A Novel PCSK9-Targeting Monoclonal Antibody for Hypercholesterolemia
13 February 2025
Recaticimab, a monoclonal antibody developed by Hengrui Medicine, was approved by the National Medical Products Administration (NMPA) in China on January 8, 2025.
Read →
Global First Drug Approvals in January 2025: A Comprehensive Review of Novel Therapies
Drug Highlight
16 min read
Global First Drug Approvals in January 2025: A Comprehensive Review of Novel Therapies
12 February 2025
In this article, we present a comprehensive overview of drugs that received their first global approvals in January 2025, along with an analysis of these therapies.
Read →